Search

Researchers led by scientists at Memorial Sloan Kettering Cancer Center have now identified fundamentally novel regulatory mechanisms of PTEN function. The findings from two related studies are published in the January 12 issue of Cell.

… Friday, January 12, 2007 PTEN is one of the most commonly mutated tumor suppressor genes. It is an antagonist for many cellular growth, proliferation and survival processes. When mutated or deleted, it causes cancers of the prostate, breast, colon, and brain. Researchers led by scientists at Memorial

New MSK research identified a way to reduce toxicity in CAR T cell therapy; discovered a division of labor in DNA repair that suggests a possible therapeutic strategy for certain cancers; developed a new method to enable imaging of two PET tracers simultaneously; found biomarkers that could help predict outcomes in HER2-positive metastatic esophagogastric cancer; and made progress toward improving options for patients with early-stage, potentially indolent cancers.

… Monday, July 17, 2023 New research from  Memorial Sloan Kettering Cancer Center (MSK)  and the  Sloan Kettering Institute  — a hub for basic science and translational research within MSK — discovered a division of labor in DNA repair that suggests a possible therapeutic strategy for certain cancers;

Memorial Sloan Kettering hosted its 24th annual “Thrivers” celebration to honor the patients, staff, and caregivers of the MSK Bone Marrow Transplantation (BMT) Service.

… Friday, September 13, 2019 It was a night of long hugs, standing ovations, well-earned tears, and “can you believe it?” stories, as Memorial Sloan Kettering hosted a lavish party to honor the patients, staff, and caregivers of MSK’s renowned Bone Marrow Transplant (BMT) Service . The event marked MSK

Take a look back at some of the year’s biggest news in cancer research.

… Thursday, December 27, 2018 December wouldn’t be complete without a recap of the year’s most important scientific advances in cancer. Memorial Sloan Kettering scientists published hundreds of studies this past year and weighed in as experts on many others. Below are some of the year’s highlights.   1

New research from MSK develops a method for analyzing cancer cells that survive treatment for acute myeloid leukemia; identifies a transcription factor that orchestrates natural killer cell response; and finds vepafestinib is a promising therapeutic for the treatment of RET-driven cancers.

… Friday, September 29, 2023 New research from Memorial Sloan Kettering Cancer Center (MSK) develops a method for analyzing cancer cells that survive treatment for acute myeloid leukemia; identifies a transcription factor that orchestrates natural killer cell response; and finds vepafestinib is a promising

Researchers at Memorial Sloan Kettering (MSK) report today in the New England Journal of Medicine that adult patients with acute lymphoblastic leukemia (ALL) who received chimeric antigen receptor (CAR) T cell therapy responded better if they had a small amount of disease at the time of the treatment. Compared with patients with a greater amount of disease, those in the low-disease category lived significantly longer and experienced fewer life-threatening side effects.  

… Wednesday, January 31, 2018 Researchers at Memorial Sloan Kettering (MSK) report today in the New England Journal of Medicine that adult patients with acute lymphoblastic leukemia (ALL) who received chimeric antigen receptor ( CAR ) T cell therapy responded better if they had a small amount of disease

Learn about the difference methods of colorectal cancer screening, including the at-home Cologuard test, from an expert at Memorial Sloan Kettering Cancer Center.

… Monday, March 16, 2026 You probably know that at age 45, people at average risk are advised to begin screening for colorectal cancer. And you may be aware of various screening methods, particularly colonoscopy and the widely advertised at-home test called Cologuard®. But many people have questions about

Obtenga información sobre los diferentes métodos de detección de cáncer colorrectal, incluso la prueba casera Cologuard, de una experta de Memorial Sloan Kettering Cancer Center.

… Monday, March 16, 2026 Usted probablemente sepa que, a partir de los 45 años de edad, se recomienda que las personas que corren riesgo promedio de padecer cáncer colorrectal comiencen a hacerse pruebas de detección de dicha enfermedad. También puede que conozca diversos métodos de diagnóstico, en particular

Узнайте о способах обследования на наличие рака толстой и прямой кишки, в том числе о домашнем анализе Cologuard, у специалиста Memorial Sloan Kettering Cancer Center.

… Monday, March 16, 2026 Возможно, вы знаете, что людям в возрасте от 45 лет со средним уровнем риска развития рака толстой и прямой кишки рекомендовано проходить обследования. Вам также может быть известно о различных способах такого обследования, в частности о колоноскопии и широко разрекламированном

Edward Athanasian discusses the unique challenges of operating on sarcomas and other tumors in the hand.

… Tuesday, July 24, 2018 Summary Edward Athanasian is the only surgeon in the United States who is trained in both surgical oncology and hand surgery. He is also Chief of the Hand and Upper Extremity Service at the Hospital for Special Surgery in New York City. Sarcoma is not one distinct cancer but more